Systematic review of genome wide association studies (GWAS) of epilepsy identifies common risk variants and associated genes

[1]S. Jacobs, [1] O. Wootton, [1,2] V Ives-Deliperi, [1,3] L. Tucker, [1] D.J Stein, [4] S. Dalvie

[1] Neuroscience Institute, Department of Mental Health and Psychiatry, University of Cape Town, South Africa

[2] Constantiaberg Medi Clinic, Cape Town, South Africa

[3] Neuroscience Institute, Division of Neurology, University of Cape Town, South Africa

[4] Division of Human Genetics, Department of Pathology, University of Cape Town, South Africa

Abstract

Epilepsy is one of the most prevalent neurological disorders, affecting 50 million individuals worldwide. The aetiology of epilepsy is known to have genetic contributions, yet the results obtained from genome-wide association studies (GWAS) conducted on epilepsy lack consistency. Therefore, it may be useful to conduct a systematic review of the existing research. The objective of this study was to systematically review GWAS for epilepsy to identify risk variants for this disorder. This systematic review was conducted in accordance with the updated PRISMA protocol. The quality of each of the studies was evaluated using the Q-Genie tool. A total of 10 studies were included for the full extraction, analysis, and quality assessment. Across the identified studies, 51 SNPs, located in 39 genes, were significantly associated with epilepsy at the genome-wide level. Several of these significant SNPs are located in ion channel genes. Three genes, in particular, *SCN1A*, *PADI6* and *FANCL*, had the highest number of associated SNPs. Both *SCN1A* and *FANCL* were found to be associated with several epilepsy subtypes, including generalized and focal epilepsy syndromes. *PADI6* was associated with generalized epilepsy only. Genes which encode for ion and transport channels, transcription factors, ubiquitin ligase and transporter proteins were identified as genes which may be involved in the aetiology of epilepsy disorders and should be further explored. Future research should also include populations of more diverse ancestries as this may reveal unique and important epilepsy-associated genes.

Keywords: Single nucleotide polymorphism (SNP), sodium channels, genome wide association studies.

Introduction

Epilepsy is a neurological disorder, characterized by a combination of clinical and electroencephalographic (EEG) features and affects approximately 50 million individuals worldwide[1]. Epilepsy has four main classification types, namely, i) focal, ii) generalized, iii) combined focal and generalized and iv) unknown epilepsy[2]. Approximately 80% of epilepsy cases occur in low and middle-income countries (LMICs), with a higher incidence than in high income countries (HICs)[3]. Specifically, the incidence of epilepsy in HICs is 45 per 100 individuals per year, in comparison to 81.7 per 100 per year in LMICs[4].

Many forms of epilepsy have a genetic component, with heritability differing per epilepsy type[5]. In 2017, the International League Against Epilepsy taskforce advised that the term genetic generalized epilepsy (GGE) may be used to classify and group a broader range of epilepsy syndromes which are characterized by generalized seizure types and spike wave, which include generalized epilepsy (GE) syndromes. GE has an estimated heritability of 31% [6]. Idiopathic generalized epilepsy (IGE), is a sub-type of GGE and includes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and generalized tonic-clonic seizures alone (GTCA)[1,6].

Over 95% of epilepsy patients are diagnosed with common forms of epilepsy, which include IGE, temporal and frontal lobe epilepsy (TLE/FLE) and benign Rolandic epilepsy (BRE)[6]. These forms of epilepsy may involve multiple genetic variants, interacting with environmental factors[7]. Such genetic variants have been identified by genome-wide association studies (GWAS)[8]. Indeed, over the last decade, multiple GWAS for epilepsy have been conducted, mainly in European-ancestry and Asian-ancestry individuals[9]. However, findings from different studies have been inconsistent. Here we undertook a systematic review of GWAS for epilepsy in order to identify genetic risk variants for this condition.

Materials and Methods

This systematic review was registered on PROSPERO in March 2022 (ID: CRD42022308427). The PRISMA[10] workflow (**Figure 1**) was used to identify all relevant studies published between the years 2010-2022. We had selected the time period based on the fact that the first GWAS on epilepsy was published in 2010. Filters were included on all searches, where applicable, to identify results for studies that included only human

participants and were published in English. Duplicates were removed using Endnote's native tool before exporting into Covidence for title, abstract and full text screening[11]. Studies were included if they were published in English, were primary GWAS, used human participants and were published between 2010-2022. Studies were excluded if they assessed variants other than single nucleotide polymorphisms (SNPs). We included GWAS performed for any epilepsy type and did not limit our search to specific sub-types. EbscoHost, PubMed, Scopus, Web of Science and the University of Cape Town's (UCT) Primo were selected as the relevant databases for searching. Search strings combining all possible MeSH terms, as well as search strings combining only two terms at a time were run. Search strings included variations of "(GWAS)", "((genome wide association stud*)/(analys*))", "(genome wide stud*)/(analys*))", "(epileps*)" and "(seizure disorders)".

Study characteristics, which included participant number, number of significant SNPs, sequencing platform, epilepsy type, method of diagnosis and ancestry of participants were tabulated (**supplementary materials, Table S1.1**). All SNPs reaching genome-wide significance ($p < 5 \times 10^{-8}$), along with their minor allele frequencies (MAF), effect allele, quality score and associated epilepsy type, were extracted (**Table 1**).

The SNPs which reached genome-wide significance were grouped according to their associated candidate gene. The primary function of each of the genes was established using the Uniprot database[12]. The associated epilepsy sub-type term used was based on the classification term used in the respective GWAS.



Figure 1 PRISMA 2020 workflow for the current systematic review.

Table 1 GWASs of epilepsy, with genome-wide significant SNPs only ($p < 5 \times 10^{-8}$).

Study	Sample size		Phenotype	SNP ID	Effect Allele	MAF	P-value	Quality Score	Risk of Bias
	Cases	Controls							
EPICURE & EMINet Consortium, 2012	3,020 [c]	3,350 [d]	GGE	rs13026414 rs72823592	T/C A/G	0.373 0.190	2.4×10^{-9} 9.35×10^{-9}	1.0027 [a]	31
			GAE	rs10496964	T/C	0.138	9.09×10^{-9}		
			JME	rs12059546	G/A	0.232	4.14×10^{-8}		
Guo *et al*., 2012	1,087	3,444	Symptomatic FE, cryptogenic FE	rs2292096	G	*Discovery* 0.120 *Replication* 0.139	*Discovery* 6.76x10-6 *Replication* 0.00038 (*Combined: 1.04×10^{-8}*)	1.15 [b]	51
Kasperaviciute *et al*., 2013	1,977 [a]	11,143 [b]	Mesial temporal lobe epilepsy with hippocampal sclerosis	rs7587026	A	0.334	1.53×10^{-3}	N/A	44
International League Against Epilepsy Consortium on Complex Epilepsies, 2014	8,696	8,696	GGE, FE	rs6732655 rs28498976	A A	0.22 0.46	$8{\cdot}71 \times 10^{-10}$ $5{\cdot}44 \times 10^{-9}$	1.03	53
			GGE	rs2947349	C	0.26	$9{\cdot}99 \times 10^{-9}$	1.05	
International League Against Epilepsy Consortium on	15,212	29,677	GE, FE, CAE, JME, FE+HS	rs4671319 rs6432877 rs4638568	G G A	0.44 0.26 0.06	8.1×10^{-9} 1.7×10^{-13} 4.0×10^{-8}	EUR: 1.2514 AA: 0.9977 Asian: 1.045	53

Complex Epilepsies, 2018									
			FE	rs2212656	A	0.26	7.3×10^{-9}	EUR: 1.197 AA: 0.9977 Asian: 1.045	
			GE	rs4665630	C	0.13	4.3×10^{-8}	EUR: 1.2514 AA: 0.9977	
				rs1402398	G	0.36	1.2×10^{-11}		
				rs11890028	G	0.27	4.7×10^{-8}		
				rs887696	C	0.34	3.0×10^{-8}		
				rs1044352	T	0.42	2.2×10^{-9}		
				rs11943905	T	0.27	3.9×10^{-8}		
				rs4596374	C	0.45	7.2×10^{-10}		
				rs68082256	A	0.20	1.7×10^{-9}		
				rs13200150	G	0.30	5.9×10^{-9}		
				rs4794333	C	0.38	6.8×10^{-9}		
				rs2833098	G	0.38	1.7×10^{-8}		
			CAE	rs12185644	C	0.29	4.5×10^{-10}	EUR: 1.094	
				rs13020210	G	0.20	2.4×10^{-8}		
			JME	rs1046276	T	0.34	2.5×10^{-11}	EUR: 1.1447	
			FE+HS	rs1991545	A	0.04	1.3×10^{-11}	EUR: 1.094	
				rs1318322	G	0.14	6.7×10^{-9}		
Buono *et al*., 2021*	2,220	14,448	GE: EUR (METAL)	rs71644049 rs71644048 rs36067110	Not specified	Not specified	2.93×10^{-8}: 3.05×10^{-8} 2.86×10^{-8} 1.70×10^{-8}	Not specified	51

				rs34018214 17-77865302			3.98×10^{-8}		
			GE: Trans (MANTRA)	rs5928634 rs5927306 rs71644049 17-77865302 rs71644048 rs36067110	Not specified	Not specified	6.39** 6.23** 6.21** 6.16** 6.15** 6.02**	Not specified	
			FE: AA (METAL)	rs114591251 19-5961503 rs12554609 rs58069848	Not specified	Not specified	3.66×10^{-8} 2.15×10^{-8} 1.08×10^{-9} 3.83×10^{-8}	Not specified	
			FE: EUR (METAL)	X-73537149			2.45×10^{-8}		
			Focal epilepsy: Trans (MANTRA)	rs12554609 19-5961503 X-73537149 rs114591251 rs58069848	Not specified	Not specified	7.25** 6.30** 6.29** 6.15** 6.13**	Not specified	
Song *et al.*,2021	26,352	774,517	GG, FE, unclassified epilepsy	rs11890028 rs11978015 rs28634186	T/G G/A T/C	Not specified	7.76×10^{-13} 9.26×10^{-9} 4.39×10^{-8}	1.03	57
Suzzuki *et al.*, 2021	1,825	7,975	GGE (including symptomatic and uncategorised)	rs66614071 rs79105258 rs149212747 rs3782886 rs11066001	G A A C C A C A	0.172 0.218 0.777 0.234 0.219 0.221 0.221 0.221	2.19×10^{-9} 3.04×10^{-9} 8.57×10^{-10} 2.04×10^{-8} 4.06×10^{-9} 7.89×10^{-9} 4.50×10^{-9} 4.80×10^{-9}	1.11 (GGE) 1.05 (GAE) 1.06 (JME)	57

	rs11066015	T	0.221	3.13×10^{-8}
	rs4646776	C	0.222	3.61×10^{-8}
	rs671	C	0.538	1.14×10^{-8}
	rs11066132			
	rs116873087			
	rs7139170			
Status epilepticus	rs149212747	A	0.777	8.57×10^{-8}

GE: Generalized epilepsy, GGE: Genetic generalized epilepsy, GAEs: Genetic absence epilepsy; JME: Juvenile myoclonic epilepsy, FE: Focal epilepsy, CAE: Childhood absence epilepsy, MTLE-HS + FS: Mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, FE+HS: Focal epilepsy with hippocampal sclerosis.

[a] Genomic inflation factor post logistic regression: GGE (1.006), GAE (0.988), JME (0.999)

[b] Genomic inflation factor after adjustment of stratification: 1.02.

EUR: European, AA: African American.

*Statistically significant for METAL ($p \leq 5 \times 10-8$) or MANTRA (Bayes ≥ 6.00), **where applicable Bayes Factor shown.

Critical appraisal of studies

To appraise the quality of the reviewed studies, the Q-Genie tool was used[13]. This tool consists of 11 items rated on a 7-point likert scale which assess the following domains: 1) scientific basis for development of the research questions, 2) ascertainment of comparison groups (cases/controls), 3) technical and non-technical classification of genetic variants tested, 4) classification of the outcome, 5) discussion of source of bias, 6) appropriateness of sample size and power, 7) description of planned statistical analysis, 8) statistical methods applied, 9) test of assumptions used and 10) interpretation of results[13]. The following cut-off points were used to determine the quality of each study; scores of ≤35 on the Q-Genie tool indicated poor quality, >35 and ≤45 indicated moderate quality, and >45 indicated good quality[13]. A second independent reviewer was involved in the screening and critical appraisal as a means to decrease any possible bias, and increase accuracy of relevant studies.

Results

Overview of literature search

A total of 6,783 studies were identified across all databases using the search strategy described and shown in **Figure 1**. After removal of duplicates (*n* = 5,792) and entries which did not fit the inclusion criteria (*n* = 563); a final total of 428 records were uploaded to Covidence[11]. Covidence automatically excluded an additional four duplicate records, resulting in a total of 424 records for title and abstract screening. A further 401 studies were excluded after screening. These exclusions were reviews, studies which combined epilepsy with a secondary neurological disorder or non-epileptic seizures (NES); and studies which focused on microRNA or copy number variants. From the 23 studies screened for full text, a further 13 studies were excluded due to their study design or outcome not meeting the inclusion criteria, resulting in a final total of 10 studies for full review.

The GWAS included for review were published between 2010-2022 with sample sizes ranging from 1,087 to 26,352 for cases and 3,444 to 774,517 for controls (**supplementary materials, Table S1.1**). The majority of studies (7 of 10) were of European ancestry, while 4 of the 10 studies included a small cohort of individuals of African ancestry. Several studies had overlapping cohorts. For example, Ishagaki *et al*., (2020)[14], Song *et al*., (2020)[9] and Suzuki *et al*., (2021)[15] utilized GWAS from BioBank Japan (BBJ)[16].

Quality assessment

Table 2 shows the SNPs which reached genome wide significance ($p < 5 \times 10^{-8}$) for each study. The majority of the studies used genomic inflation as the method of quality assessment. Overall, apart from Song *et al*., (2020)[9] and Ishigaki *et al*., (2020)[14], all studies had "good global quality", scoring >45 in Q-genie. Most studies scored between 1-2 for "other source of bias", as they did not specifically report on such biases. Most studies scored between 1-3 for "sample size and power" as they did not include a power calculation. A detailed breakdown of each study's scoring can be found in **supplementary material (Table S1.2).**

Common risk variants identified from GWAS for epilepsy

A total of 51 significant SNPs (positionally mapped to 39 genes) were identified for epilepsy across all studies (**Table 2**). From the total of 51 SNPs which reached genome-wide significance ($p < 5 \times 10^{-8}$), one SNP was identified in more than one study. Lead SNP, rs11890028, was reported in the GWAS by Song *et al*., (2021)[9] and ILAE (2018)[6], which is likely due sample overlap between these two studies.

Genes associated with epilepsy disorders

Several of the SNPs identified are located in ion channel genes. There were three genes which had the highest number of associated SNPs across studies; namely sodium channel protein type 1 subunit alpha (*SCN1A*) (number of independent significant SNPs = 5), peptidyl arginine deiminase 6 (*PADI6*) (number of independent significant SNPs = 3), and Fanconi anemia complementation group L (*FANCL*) (number of independent significant SNPs = 4). Both of the genes *SCN1A* and *FANCL* were found in cohorts of European, African and Asian ancestry. *SCN1A* was associated with all epilepsy types including mesial temporal lobe epilepsy with hippocampal sclerosis and febrile seizures (MTLEHS + FS). *FANCL* was also associated with all epilepsy, including childhood absence epilepsy (CAE). *PADI6* was significantly associated with GE specifically in individuals of European ancestry.

A number of SNPs were identified in individuals of Asian ancestry only and were associated with GGE. These SNPs are located in the genes *BRAP, CUX2, RPH3A, NAA25, LINCO2356,*

ALDH2 and *ACAD10*. The gene *CAMSAP1L* was associated with both symptomatic and cryptogenic FE.

Table 2 SNPs which reached genome-wide significance ($p < 5 \times 10^{-8}$), their associated candidate genes, function, epilepsy type and ancestry.

SNP	Candidate Gene	Function	Epilepsy type	Ancestry
rs6732655	*SCN1A*	Ion channel	GGE, FE	EUR, Asian, AA
rs11890028			GE	EUR, Asian, AA
			GGE, FE	EUR, Asian, AA
rs2212656			FE	EUR, Asian, AA
rs6432877			GGE, FE	EUR, Asian, AA
rs7587026			MTLEHS + FS	EUR
rs11890028	*SCN2A*		GE	EUR, Asian, AA
rs2212656			FE	EUR, Asian, AA
rs6432877			GGE, FE	EUR, Asian, AA
rs2212656	*SCN3A*		GE	EUR, Asian, AA
rs6432877			FE	EUR, Asian, AA
rs11890028			GGE, FE	EUR, Asian, AA
rs11943905	*GABRA2*		GE	EUR, Asian, AA
rs4596374	*KCNN2*		GE	EUR, Asian, AA
rs1991545	*KCNAB1*		FE+HS	EUR
rs2833098	*GRIK1*		GE	EUR, Asian, AA
rs887696	*STAT4*	Transcription factors	GE	EUR, Asian, AA
rs10496964	*ZEB2*		GAE,	EUR
rs13020210			CAE	EUR
rs12185644	*BCL11A*		CAE	EUR
rs4671319			GGE, FE	EUR, Asian, AA
rs1402398			GE,	EUR, Asian, AA
rs1991545	*C3orf33*		FE + HS	EUR
rs66614071, rs79105258	*CUX2*		GGE (including	Asian

			symptomatic and uncategorised)	
rs7282359	*NFE2L1*		GGE	EUR
rs1402398	*FANCL*	Ubiquitin ligase	GE	EUR, Asian, AA
rs4671319, rs6732655			GGE, FE	EUR, Asian, AA
rs12185644			CAE	EUR
rs2947349			GGE	EUR, Asian, AA
rs11066001	*BRAP*		GGE (including symptomatic and uncategorised)	Asian
rs3782886			GGE (including symptomatic and uncategorised)	Asian
rs4638568	*HEATR3*	Transporter	GGE, FE	EUR, Asian, AA
rs11890028	*TTC21B*		GGE, FE	EUR, Asian, AA
rs2212656			FE	EUR, Asian, AA
rs6432877			GGE, FE	EUR, Asian, AA
rs1991545	*SLC33A1*		FE+HS	EUR
rs28498976	*PCDH7*	Cell-cell recognition	GGE, FE	EUR, Asian, AA
rs1044352			GE	EUR, Asian, AA
rs4665630	*KLHL29*	Protein coding	GE	EUR, Asian, AA
rs13200150	*PTPRK*		GE	EUR, Asian, AA
rs4638568	*BRD7*	Histone modification	GGE, FE	EUR, AA, Asian
rs68082256	*ATXN1*	Chromatin binding factor	GE	EUR, Asian, AA
rs1046276	*STX1B*	Synaptic transmission	JME	EUR
rs36067110*, rs71644049*, rs71644048*	*PADI6*	Protein deamination	GE	EUR, AA
rs34018214*	*PAD14*	Protein deamination	GE	EUR
rs4646776, rs671	*ALDH2*	Detoxification enzyme	GGE (including symptomatic and uncategorised)	Asian
rs11066015	*ACAD10*	Beta oxidation	GGE (including symptomatic and uncategorised)	Asian
rs12059546	*CHRM3*	Protein-coupled receptor	JME	EUR
rs28634186	*TNKS*	Histone binding	GGE, FE, unclassified	EUR, Asian, AA
rs2292096	*CAMSAP1L1*	Microtubule minus-end binding	Symptomatic/cryptogenic FE	Asian
rs4794333	*PNPO*	Pyridoxine	GE	EUR, Asian,

		metabolism		AA
rs5927306*	*TMEM47*	Regulator of cell organization	GE	EUR, AA
rs5928634*			GE	EUR, AA
rs1318322	*GJA1*	Regulator of bladder capacity	FE + HS	EUR
rs2947349	*VRK2*	Cell proliferation	GGE	EUR, Asian, AA
rs11978015	*GRM3*	Excitatory neurotransmitter	FE, GGE	EUR, Asian, AA
19-5961503*, rs58069848*	*RANBP3*	Protein binding	FE	EUR, AA
rs11459125*			FE	EUR, AA
rs12554609*	*ASS1*	Catalyser in urea cycle	FE	EUR, AA
rs7139170	*RPH3A*	Unspecified	GGE (including symptomatic and uncategorised)	Asian
rs116873087, rs11066132	*NAA25*		GGE (including symptomatic and uncategorised)	Asian
rs149212747	*LINC02356*		GGE (including symptomatic and uncategorised), Status epilepticus	Asian
rs13026414	*LOC101927235*		GGE	EUR
17-77865302	-		GE	EUR

GE: Generalized epilepsy, GGE: Genetic generalized epilepsy, GAEs: Genetic absence epilepsy; JME: Juvenile myoclonic epilepsy, FE: Focal epilepsy, CAE: Childhood absence epilepsy, MTLE-HS + FS: Mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, FE+HS: Focal epilepsy with hippocampal sclerosis.
EUR: European, AA: African American.
*Statistically significant for METAL ($p \leq 5 \times 10{-}8$) or MANTRA (Bayes $\geq$ 6.00).

Discussion

In this study, we systematically reviewed the results of GWAS for epilepsy. Most of the assessed studies included participants who were predominately of European and Asian ancestry. We found that SNPs located in genes encoding ion channels, transcription factors, ribosomal protein transporters, ubiquitin ligase and protein deamination are the most frequently reported to be associated with epilepsy. Of these genes, *SCN1A*, *PADI6* and *FANCL* had the highest number of SNPs associated with epilepsy across European and Asian cohorts.

From our systematic review, three ion channel genes, *SCN1A*; *PADI6*; and *FANCL*, contained the highest number of associated SNPs. This is in line with previous animal studies which indicated that ion channel genes account for approximately 25% of the genes identified for

epilepsy[17]. Further, due to the high number of ion channel genes implicated in epilepsy disorders, epilepsy is sometimes classified as a disease of "ion channelopathies"[18,19]. Ion channels play a crucial role in both the generation and propagation of neuronal action potentials in the central nervous system (CNS), therefore a disturbance in neuronal ionic flow, due to variation in an ion channel gene, may contribute towards the development of a seizure[20].

SCN1A encodes a voltage gated sodium channel (VGSC) and is expressed mainly in the CNS. VGSCs play a key role in both the propagation and generation of action potentials within neural cells[21,22]. Mutations occurring within VGSC genes are the most common cause of genetic epilepsies[23]. *SCN1A* was found to be associated with GE, including FE and unclassified epilepsy; and MTLEHS + FS across European, African and Asian ancestry cohorts,. The SNP rs7587026, which is located in *SCN1A*, specifically, has been reported to be associated with MTLEHS + FS[24]. In a recent study by Silvennoien et al. (2022), zebrafish were used to study the overexpression of *SCN1A* and reported a possible connection between increased expression of *SCN1A* in the hippocampus, reduced hippocampal volumes, and an increased susceptibility to temperature-induced seizures[25]. The findings by Silvernnoien and colleagues provides experimental evidence which links altered *SCN1A* expression to changes in the brain structure and seizure susceptibility. Mutations of this gene can lead to disruptions in the neural activity, contributing to various forms of epilepsy. SNP rs7587026 and its specified association with MTLEHS + FS highlight the genetic complexity underlying epilepsy.

Two other sodium ion channel genes have been reported to be associated with epilepsy, *SCN2A* and *SCN3A*. *SCN2A* variants have been associated with a number of neurodevelopmental disorders and accounts for approximately 1% of all epileptic encephalopathies, which include GE with febrile seizures, early infantile epileptic encephalopathy (type 11), benign familial infantile seizures (type 3) and West syndrome[26]. Similarly, variation within *SCN3A* has been associated with developmental and epileptic encephalopathy with or without malformations of cortical development; or malformations of cortical development with or without mild focal epilepsy [27].

PADI6 (Peptidyl arginine deiminase 6) was identified as the second gene with the highest number of SNPs associated with epilepsy, even though there had been no previous

associations between this gene and epilepsy[29]. *PADI6* encodes an enzyme that deaminates proteins in molecular pathways related to epigenetic regulation of histones and autoantibody formation, suggesting that epigenetic control of gene expression may play a role in epileptogenesis[29]. This gene was found to only be associated with GE in individuals of European ancestry, with no genome-wide significant SNPs in individuals of other ancestries[30].

FANCL (fanconi anemia complementation group L), which encodes an ubiquitin ligase protein[31], was the third gene to have the most SNPs associated with GE and CAE epilepsy syndromes. *FANCL* plays a role in the normal functioning of the immune system and the plasticity of the CNS for gene regulation[32] Plasticity refers to the ability of the brain to reorganize itself by forming new neural connections and modifying existing ones in response to changes in the environment[33]. In individuals with epilepsy, *FANCL* variants may lead to abnormal changes in the brain structure and function, potentially contributing to the development or maintenance of epilepsy[34]. Two SNPs, rs3782886, rs11066001, located in the gene, *BRAP*, which also encodes a ubiquitin ligase protein, were associated with GGE, including symptomatic and unclassified epilepsy in individuals of Asian (Japanese) ancestry[33]. Genetic variations within ubiquitin ligase protein-encoding genes, such as *FANCL* and *BRAP* may potentially contribute to the development or persistence of epilepsy due to the impact these variations have on immune system functioning, CNS plasticity and brain structure.

Several transporter channel associated genes, namely *HEATR3* (rs4638568), *TTC21B* (rs6432877, rs11890028) and *SLC33A1* (rs1991545) were found in the GWAS conducted by the International League Against Epilepsy (2018) in their trans-ethnic meta-analysis group, yet not in the GWAS conducted by Song and colleagues (2021), despite an overlap in cohorts[6,10]. The SNPs which have been suggested to be associated to both *HEATR3* and *SLC33A1* were novel, having not been previously associated with epilepsy. The SNP rs4638568 was associated with all epilepsy groups, while rs1991545 was associated with FE only. The exact role of these genes in epilepsy disorders has not been well established and requires further investigation to better understand how variations of these genes influence the development and progression of epilepsy.

Despite identifying the lead SNP (rs11890028) in two of the studies, we were unable to conduct a meta-analysis due to an overlap in participating cohorts between the GWAS conducted by Song *et al.*, (2021) and ILAE (2018)[10,6]. In 2022 the ILAE released updated guidelines for the classification of epilepsy syndromes. However, we have decided to keep the classification term used at the time of each of the respective GWAS[1,7,36,37,38,39]. This may be viewed as a limitation as epilepsy classification differs across the studies reviewed here. For example, Kasperaviciute and colleagues (2010) investigated what is now known as FE. However, at the time the GWAS was published, the 1989 International League Against Epilepsy Commission on Classification and Terminology was in effect, where FE was known as partial epilepsy[40].

Conclusion

Taken together, the results of this study illustrate the value of systematically reviewing GWAS findings to prioritise risk variants for epilepsy for future follow-up investigation. Genes within ion and transport channels, in addition to genes encoding transcription factors, ubiquitin ligase and transporter proteins should be further explored to assess their roles in epilepsy. The results of this study assist in identifying the top candidate genes and their associated SNPs for further investigation of the mechanisms underlying various epilepsy syndromes. Additionally, the majority of the SNPs and associated genes appear to be involved in more than one epilepsy type, supporting a view that seizure disorders involve overlapping phenomenological and psychobiological dimensions. Given the lack of diversity of those studied in the research reviewed here, future studies should also include participants of more diverse ancestries.

Acknowledgements

The work reported herein was made possible through funding by the South African Medical Research Council (SAMRC) through its Division of Research Capacity Development under the Bongani Mayosi National Health Scholars Programme from funding received from the Public Health Enhancement Fund / South African National Department of Health. The content hereof is the sole responsibility of the authors and does not necessarily represent the official views of the SAMRC.

Author contributions

S. J conceptualization, formal analysis (equal), funding acquisition, investigation, methodology, project administration, resources, validation, visualization, writing-original draft preparation; **O.W** formal analysis (equal), writing-reviewing & editing; **V I-D** supervision; writing-reviewing & editing (supporting), **L.T** supervision; writing-reviewing & editing (supporting), **D.J S**; conceptualization (supporting), supervision, writing- reviewing & editing (equal); **S.D** conceptualization (supporting), project administration (supporting), supervision (lead), validation (supporting), visualization (supporting), writing- reviewing & editing (equal)

Declaration of conflict of interests and ethical statement

None of the authors have any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and a□rm that this report is consistent with those guidelines. This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the University of Cape Town Human Research Ethics Committee (183/2022).

References

1. Riney, K., Bogacz, A., Somerville, E., Hirsch, E., Nabbout, R., Scheffer, I. E., Zuberi, S. M., Alsaadi, T., Jain, S., French, J., Specchio, N., Trinka, E., Wiebe, S., Auvin, S., Cabral□Lim, L., Naidoo, A., Perucca, E., Moshé, S. L., Wirrell, E. C., & Tinuper, P. (2022). International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. https://doi.org/10.1111/epi.17240
2. Scheffer, I. E., Berkovic, S., Capovilla, G., Connolly, M. B., French, J., Guilhoto, L., Hirsch, E., Jain, S., Mathern, G. W., Moshé, S. L., Nordli, D. R., Perucca, E., Tomson, T., Wiebe, S., Zhang, Y. H., & Zuberi, S. M. (2017). ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia, 58(4), 512-521. https://doi.org/10.1111/epi.13709
3. Meyer, A.-C., Dua, T., Ma, J., Saxena, S., & Birbeck, G. (2010). Global disparities in the epilepsy treatment gap: a systematic review. Bulletin of the World Health Organization, 88(4), 260-266. https://doi.org/10.2471/BLT.09.064147
4. Ngugi, A. K., Kariuki, S. M., Bottomley, C., Kleinschmidt, I., Sander, J. W., & Newton, C. R. (2011). Incidence of epilepsy: a systematic review and meta-analysis. Neurology, 77(10), 1005-1012. https://doi.org/10.1212/WNL.0b013e31822cfc90
5. Hirsch, E, French, J, Scheffer, IE, Bogacz, A, Alsaadi, T, Sperling, MR, et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022; 63: 1475– 1499. https://doi.org/10.1111/epi.17236
6. International League Against Epilepsy Consortium on Complex, E. (2018). Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in

the common epilepsies. Nature Communications, 9(1), 5269-5269. https://doi.org/10.1038/s41467-018-07524-z
7. Epicure Consortium., (2012) Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32. Hum. Mol. Genet. 21:5359–5372. https:// doi.org/ 10.1093/hmg/dds373.
8. Chang, M., He, L., & Cai, L. (2018). An Overview of Genome-Wide Association Studies. Methods Mol Biol, 1754, 97-108. https://doi.org/10.1007/978-1-4939-7717-8_6
9. Song, M., Liu, J., Yang, Y., Lv, L., Li, W., & Luo, X.-J. (2021). Genome-Wide Meta-Analysis Identifies Two Novel Risk Loci for Epilepsy. Frontiers in Neuroscience, 15. https://doi.org/10.3389/fnins.2021.722592
10. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
11. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org.
12. UniProt Consortium (2007). The Universal Protein Resource (UniProt). Nucleic acids research, 35(Database issue), D193–D197. https://doi.org/10.1093/nar/gkl929
13. Sohani, Z. N., Meyre, D., de Souza, R. J., Joseph, P. G., Gandhi, M., Dennis, B. B., Norman, G., & Anand, S. S. (2015). Assessing the quality of published genetic association studies in meta-analyses: the quality of genetic studies (Q-Genie) tool. BMC Genetics, 16(1), 50. https://doi.org/10.1186/s12863-015-0211-2
14. Nagai, A., Hirata, M., Kamatani, Y., Muto, K., Matsuda, K., Kiyohara, Y., Ninomiya, T., Tamakoshi, A., Yamagata, Z., Mushiroda, T., Murakami, Y., Yuji, K., Furukawa, Y., Zembutsu, H., Tanaka, T., Ohnishi, Y., Nakamura, Y., BioBank Japan Cooperative Hospital Group, & Kubo, M. (2017). Overview of the BioBank Japan Project: Study design and profile. Journal of epidemiology, 27(3S), S2–S8. https://doi.org/10.1016/j.je.2016.12.005
15. Oyrer J, Maljevic S, Scheffer IE, Berkovic SF, Petrou S, Reid CA. (2018) Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies. Pharmacol Rev. 70(1):142-173. https://doi: 10.1124/pr.117.014456.
16. Reid, C. A., Kim, T., Phillips, A. M., Low, J., Berkovic, S. F., Luscher, B., & Petrou, S. (2013). Multiple molecular mechanisms for a single GABAA mutation in epilepsy. Neurology, 80(11), 1003–1008. https://doi.org/10.1212/WNL.0b013e3182872867
17. Wallace, R. H., Wang, D. W., Singh, R., Scheffer, I. E., George, A. L. Jr., Phillips, H. A., et al. (1998). Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel β1 subunit gene SCN1B. Nat. Genet. 19, 366–370. doi: 10.1038/1252
18. Raimondo, J. V., Burman, R. J., Katz, A. A., and Akerman, C. J. (2015). Ion dynamics during seizures. Front. Cell Neurosci. 9:419. doi: 10.3389/fncel.2015.00419
19. Bechi G, Rusconi R, Cestèle S, Striano P, Franceschetti S, Mantegazza M. Rescuable folding defective NaV1.1 (SCN1A) mutants in epilepsy: properties, occurrence, and novel rescuing strategy with peptides targeted to the endoplasmic reticulum. (2015) Neurobiol Dis. 75:100-14. https://doi.org/10.1016/j.nbd.2014.12.028.
20. Nelson D.L, Cox M.M (2013) Publisher: Susan Winslow, 6th ed. New York, NY: WH Freeman Company

21. Ademuwagun IA, Rotimi SO, Syrbe S, Ajamma YU, Adebiyi E. (2021) Voltage Gated Sodium Channel Genes in Epilepsy: Mutations, Functional Studies, and Treatment Dimensions. Front Neurol. 12:600050. https://doi.org/10.3389/fneur.2021.600050.
22. Kasperavičiūtė, D., Catarino, C. B., Matarin, M., Leu, C., Novy, J., Tostevin, A., Leal, B., Hessel, E. V. S., Hallmann, K., Hildebrand, M. S., Dahl, H.-H. M., Ryten, M., Trabzuni, D., Ramasamy, A., Alhusaini, S., Doherty, C. P., Dorn, T., Hansen, J., Krämer, G., & Steinhoff, B. J. (2013). Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A. Brain, 136(10), 3140–3150. https://doi.org/10.1093/brain/awt233
23. Silvennoinen, K., Gawel, K., Tsortouktzidis, D. et al. SCN1A overexpression, associated with a genomic region marked by a risk variant for a common epilepsy, raises seizure susceptibility. Acta Neuropathol **144**, 107–127 (2022). https://doi.org/10.1007/s00401-022-02429-0
24. Reynolds, C., King, M. D., & Gorman, K. M. (2020). The phenotypic spectrum of SCN2A-related epilepsy. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 24, 117–122. https://doi.org/10.1016/j.ejpn.2019.12.016
25. Helbig KL, Goldberg EM.(2021) SCN3A-Related Neurodevelopmental Disorder. Gene Reviews
26. Buono R.J. (2013) Genome wide association studies (GWAS) and common forms of human epilepsy. Epilepsy Behav. 28:S63–S65. https://doi.org 10.1016/j.yebeh.2012.07.006.
27. Jang, B., Ishigami, A., Maruyama, N., Carp, R. I., Kim, Y. S., & Choi, E. K. (2013). Peptidylarginine deiminase and protein citrullination in prion diseases: strong evidence of neurodegeneration. Prion, 7(1), 42–46. https://doi.org/10.4161/pri.22380
28. Buono, R. J., Bradfield, J. P., Wei, Z., Sperling, M. R., Dlugos, D. J., Privitera, M. D., French, J. A., Lo, W., Cossette, P., Schachter, S. C., Basehore, H., Lohoff, F. W., Grant, S. F. A., Ferraro, T. N., & Hakonarson, H. (2021). Genetic Variation in PADI6-PADI4 on 1p36.13 Is Associated with Common Forms of Human Generalized Epilepsy. Genes, 12(9), 1441. https://doi.org/10.3390/genes12091441
29. Aratani, S., Fujita, H., Yagishita, N., Yamano, Y., Okubo, Y., Nishioka, K., & Nakajima, T. (2017). Inhibitory effects of ubiquitination of synoviolin by PADI4. Molecular Medicine Reports, 16, 9203-9209. https://doi.org/10.3892/mmr.2017.7764
30. Puderbaugh M, Emmady PD. Neuroplasticity. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557811/
31. Jarero-Basulto, J. J., Gasca-Martínez, Y., Rivera-Cervantes, M. C., Ureña-Guerrero, M. E., Feria-Velasco, A. I., & Beas-Zarate, C. (2018). Interactions Between Epilepsy and Plasticity. Pharmaceuticals (Basel, Switzerland), 11(1), 17. https://doi.org/10.3390/ph11010017
32. Suzuki, T., Koike, Y., Ashikawa, K., Otomo, N., Takahashi, A., Aoi, T., Kamatani, N., Nakamura, Y., Kubo, M., Kamatani, Y., Momozawa, Y., Terao, C. & Yamakawa, K. (2021), Genome-wide association study of epilepsy in a Japanese population identified an associated region at chromosome 12q24. Epilepsia, 62: 1391-1400. https://doi.org/10.1111/epi.16911
33. Ba-Diop, A., Marin, B., Druet-Cabanac, M., Ngoungou, E. B., Newton, C. R., & Preux, P.-M. (2014). Epidemiology, causes, and treatment of epilepsy in sub-Saharan Africa. The Lancet Neurology, 13(10), 1029-1044. https://doi.org/https://doi.org/10.1016/S1474-4422(14)70114-0